Latest News

Date Title Topic
28 Sep 2015 ESMO @ ECC 2015: Comprehensive Genomic Profiling Detects High Frequency of ERBB2 Extracellular Domain Mutations in Multiple Cancer Types Personalised medicine - Translational research
28 Sep 2015 ESMO Commentary: A new promise for a rare skin cancer Cancer Immunology and Immunotherapy
28 Sep 2015 ESMO Commentary: Genomic landscape in lung cancer: steps forward in rapidly identifying genomic alterations Melanoma and other skin tumours - Lung and other thoracic tumours
28 Sep 2015 ESMO Commentary: Preserving fertility in breast cancer patients: new promises Breast cancer
28 Sep 2015 ESMO @ ECC 2015: Comprehensive Genomic Profiling of BRAF in a Large Series of Lung Cancer Samples Translational research - Lung and other thoracic tumours
28 Sep 2015 ESMO @ ECC 2015: Response to EGFR Agents in Combination With Chemotherapy Demonstrated in Patients with Metastatic Colorectal Cancer of Rare KRAS Molecular Subtype Gastrointestinal cancers - Anticancer agents & Biologic therapy
28 Sep 2015 ESMO Commentary: Preliminary Results from PERUSE Study Increase Treatment Options in HER-Positive Patients with Metastatic Breast Cancer Breast cancer
27 Sep 2015 ESMO Commentary: Immune therapy brings new treatment options for lower GI cancers Gastrointestinal cancers - Cancer Immunology and Immunotherapy
27 Sep 2015 ESMO Commentary: The variable access to best cancer care in Europe may affect clinical outcomes and survival in older patients Bioethics, legal and economic issues
27 Sep 2015 ESMO @ ECC 2015: Progression-Free Survival Prolonged with Everolimus in Patients with Advanced Lung/Gastrointestinal Neuroendocrine Tumours Endocrine and neuroendocrine tumours - Anticancer agents & Biologic therapy
27 Sep 2015 ESMO @ ECC2015: Greater Clinical Benefit Obtained in Advanced BRAFV600-mutated Melanoma with Cobimetinib/Vemurafenib Over Vemurafenib Is Consistent Across Mutation Subtypes Melanoma and other skin tumours - Anticancer agents & Biologic therapy
27 Sep 2015 ESMO @ ECC 2015: Induction with Nivolumab Followed by Ipilimumab Most Effective Temporal Approach in Non-Resectable Melanoma Melanoma and other skin tumours - Cancer Immunology and Immunotherapy
27 Sep 2015 ESMO @ ECC 2015: Blocking PD1 Shows Promise in Merkel Cell Carcinoma Melanoma and other skin tumours - Cancer Immunology and Immunotherapy
27 Sep 2015 ESMO @ ECC 2015: Novel Atezolizumab Shows Promise in Metastatic Urothelial Carcinoma Genitourinary cancers - Cancer Immunology and Immunotherapy
27 Sep 2015 ESMO @ ECC 2015: Novel Assay Developed to Determine PD-L2 Expression in Tumour Samples Pathology/Molecular biology - Cancer Immunology and Immunotherapy